BERKELEY, Calif., Dec. 9, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that it received a Letter of Reprimand from the staff of The NASDAQ Stock Market LLC on December 8, 2009 for non-compliance with NASDAQ's Listing Rule 5635(d)(2) in connection with XOMA's previously-announced common share financing completed on September 30, 2009. The issuance of this letter completed the NASDAQ staff's review of the matter which was referenced in the previously-disclosed November 13, 2009 letter to XOMA. XOMA's common shares will remain listed on The NASDAQ Global Market.
